Apeiron Investment Group Ltd. - Apr 15, 2024 Form 4 Insider Report for ATAI Life Sciences N.V. (ATAI)

Role
10%+ Owner
Signature
Apeiron Investment Group Ltd. By: /s/ Julien Hoefer, Director
Stock symbol
ATAI
Transactions as of
Apr 15, 2024
Transactions value $
$0
Form type
4
Date filed
4/17/2024, 04:15 PM
Previous filing
Mar 6, 2024
Next filing
Oct 7, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATAI Convertible Notes Other -148K -100% 0 Apr 15, 2024 Common Shares 2.37M By Apeiron Investment Group Ltd. F1, F2, F3, F4
transaction ATAI Convertible Notes Other +148K 148K Apr 15, 2024 Common Shares 2.37M By Apeiron Investment Group Ltd. F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The conversion price for the Convertible Notes is EUR 17.00 per note.
F2 Represents an exchange of Convertible Notes issued by ATAI Life Sciences AG for Convertible Notes issued by the Issuer with substantially similar terms and economics.
F3 Each Convertible Note bears a notional principal amount of EUR 1.00.
F4 The reportable securities are held by Apeiron Investment Group Ltd. ("Apeiron"). Christian Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities.